When Oncology NDAs Fail, Clinical Benefit Is Often In Question
This article was originally published in The Pink Sheet Daily
Executive Summary
Pre-submission meetings can address questions of clinically meaningful endpoints and appropriate subgroups, avoiding negative regulatory outcomes, FDA analysis suggests.
You may also be interested in...
A Cautious Guide To The Interpretation Of Clinical Trials From NEJM
Determining the success or failure of a randomized trial requires looking beyond the p-value for the primary endpoint, review articles in The New England Journal of Medicine urge.
REMS, ‘Breakthrough’ Meetings Get ‘Type B’ Tag In Revised FDA Guidance
In other modifications, FDA tells sponsors seeking Type A meetings – the most urgent category – that data packages must accompany the request.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.